These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

873 related articles for article (PubMed ID: 27955654)

  • 21. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway.
    Wang W; Chen H; Liu Z; Qu P; Lan J; Chen H; Zou L; Qiu J
    Br J Cancer; 2016 Feb; 114(3):305-13. PubMed ID: 26742010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target.
    Jia L; Yang J; Hao X; Zheng M; He H; Xiong X; Xu L; Sun Y
    Clin Cancer Res; 2010 Feb; 16(3):814-24. PubMed ID: 20103673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
    Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
    Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells.
    Nan H; Han L; Ma J; Yang C; Su R; He J
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1684-1692. PubMed ID: 29408595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway.
    Guo Y; Chang H; Li J; Xu XY; Shen L; Yu ZB; Liu WC
    Apoptosis; 2015 Aug; 20(8):1109-21. PubMed ID: 26002438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
    Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
    Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
    [No Abstract]   [Full Text] [Related]  

  • 28. MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer.
    Xu S; Ge J; Zhang Z; Zhou W
    Biomed Pharmacother; 2017 Dec; 96():634-641. PubMed ID: 29035829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application.
    Zhao Y; Sun Y
    Neoplasia; 2012 May; 14(5):360-7. PubMed ID: 22745582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptosis of human prostate cancer cells induced by marine actinomycin X2 through the mTOR pathway compounded by MiRNA144.
    Liu J; Xie S; Wu Y; Xu M; Ao C; Wang W; Zeng Q; Hu W; Li M
    Anticancer Drugs; 2016 Mar; 27(3):156-63. PubMed ID: 26645890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.
    Gómez V; Galazi M; Weitsman G; Monypenny J; Al-Salemee F; Barber PR; Ng K; Beatson R; Szokol B; Orfi L; Mullen G; Vanhaesebroeck B; Chowdhury S; Leung HY; Ng T
    Mol Cancer Ther; 2022 Apr; 21(4):667-676. PubMed ID: 35086953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. F-box and leucine-rich repeat protein 5 promotes colon cancer progression by modulating PTEN/PI3K/AKT signaling pathway.
    Yao H; Su S; Xia D; Wang M; Li Z; Chen W; Ren L; Xu L
    Biomed Pharmacother; 2018 Nov; 107():1712-1719. PubMed ID: 30257389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERα.
    Talesa VN; Ferri I; Bellezza G; Love HD; Sidoni A; Antognelli C
    Prostate; 2017 Feb; 77(2):196-210. PubMed ID: 27696457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.
    Kim S; Huang W; Mottillo EP; Sohail A; Ham YA; Conley-Lacomb MK; Kim CJ; Tzivion G; Kim HR; Wang S; Chen YQ; Fridman R
    Biochim Biophys Acta; 2010 Nov; 1803(11):1287-97. PubMed ID: 20620173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.
    Lim HJ; Wang X; Crowe P; Goldstein D; Yang JL
    Anticancer Res; 2016 Nov; 36(11):5765-5771. PubMed ID: 27793898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
    Shao G; Wang R; Sun A; Wei J; Peng K; Dai Q; Yang W; Lin Q
    Mol Cancer; 2018 Feb; 17(1):24. PubMed ID: 29455656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
    Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
    Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in
    Yan Y; An J; Yang Y; Wu D; Bai Y; Cao W; Ma L; Chen J; Yu Z; He Y; Jin X; Pan Y; Ma T; Wang S; Hou X; Weroha SJ; Karnes RJ; Zhang J; Westendorf JJ; Wang L; Chen Y; Xu W; Zhu R; Wang D; Huang H
    EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29523594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
    Yan Y; Huang H
    Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.